NEXIEN BIOPHARMA, INC. — Net Income by Fiscal Year
11 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/b648c083-8c68-4f2d-a7ad-8e113fa3681a/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2024 | $-239.1k | 2023-07-01 – 2024-06-30 | evidence 0001493152-24-041978 |
| FY 2023 | $-361.9k | 2022-07-01 – 2023-06-30 | evidence 0001493152-23-034480 |
| FY 2022 | $-626.4k | 2021-07-01 – 2022-06-30 | evidence 0001493152-22-026974 |
| FY 2021 | $-1.9M | 2020-07-01 – 2021-06-30 | evidence 0001493152-21-025119 |
| FY 2020 | $-2.7M | 2019-07-01 – 2020-06-30 | evidence 0001493152-20-018396 |
| FY 2019 | $-4.3M | 2018-07-01 – 2019-06-30 | evidence 0001493152-19-014714 |
| FY 2018 | $-1.3M | 2017-07-01 – 2018-06-30 | evidence 0001493152-18-013863 |
| FY 2017 | $-21.7k | 2016-07-01 – 2017-06-30 | evidence 0001295345-17-000219 |
| FY 2016 | $-21.0k | 2015-07-01 – 2016-06-30 | evidence 0001295345-16-000689 |
| FY 2015 | $-48.4k | 2014-07-01 – 2015-06-30 | evidence 0001295345-15-000260 |
| FY 2014 | $-536 | 2013-07-01 – 2014-06-30 | evidence 0001295345-15-000260 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
NEXIEN BIOPHARMA, INC. — all facts · Revenue · Operating Income